Zymeworks Inc. cash flow to debt ratio of -180.68% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Zymeworks Inc.'s free cash flow has increased -69.48% from $-113.11M last year to $-34.53M, signaling increasing performance

Zymeworks Inc.'s debt to equity ratio is 0.20, which means that the company's assets are healthy financed, signaling financial stability.

Zymeworks Inc.'s debt has increased relative to shareholder equity from 0.05 last year to 0.20 today, signaling weakened financials

Zymeworks Inc. has a net cash position, so leverage is healthy.

Zymeworks Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Zymeworks Inc.'s profit margin has decreased (151.25%) in the last year from -160.80% to -404.00%, signaling decreasing performance

Zymeworks Inc.'s short-term assets of $233.44M exceed its short-term liabilities of $42.32M

Zymeworks Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Zymeworks Inc.'s return on equity of -0.74%, is lower than 15.00%, indicating bad performance

Zymeworks Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Zymeworks Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Zymeworks Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Zymeworks Inc. has negative free cash flow, indicating cash burn

Zymeworks Inc.'s yearly earnings has increased -33.88% since last year from $-122.69M to $-81.13M, signaling increasing performance

Zymeworks Inc.'s yearly revenue has increased 38.87% since last year from $76.30M to $105.97M, signaling increasing performance

ROIC -0.04% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Zymeworks Inc.'s 3-year revenue CAGR of -36.43% is negative, indicating declining revenue over the past 3 years

Zymeworks Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Zymeworks Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Zymeworks Inc. has insufficient data to evaluate this check.

Zymeworks Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Zymeworks Inc. is undervalued relative to its fair value price of 720.56 based on EBITDA multiple model

Zymeworks Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Zymeworks Inc. is overvalued relative to its fair value price of -48.92 based on Earnings Fair Value model

Zymeworks Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Zymeworks Inc. has a price-to-book ratio of 0.02x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Zymeworks Inc. has a price-to-sales ratio of 47.50x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue